Company news
Aditxt, Inc. news in 2026
Aditxt, Inc.'s news releases, calls and decks from 2026, newest first.
Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million
June 9, 2026
Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection
June 8, 2026
Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer, Founder and Former CEO of $1B NYSE Enterprise Which Delivered 8.5% Dividends to Shareholders
June 2, 2026
Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders
June 1, 2026
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026
May 13, 2026
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
April 20, 2026
Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer
March 18, 2026
Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection
March 13, 2026
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026
March 4, 2026